Intratympanic gentamicin in Ménière's disease: our experience

Delgado, Laura Pérez; Rodrigo, José Antonio Lluch; Peña, María Pilar Astier

doi:10.1017/s0022215111000053

Cited by 11 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[14] In a study conducted by Delgardo LP et al in 2011 on 71 patients showed an improvement of vertigo in 84.37% of patients and hearing loss in 18.3% patients. [15] De Beer L et al in a study on 57 patients in 2007 found an improvement of vertigo in 81% of patients (Class A, 61.4%; class B, 19.3%) and hearing loss (> 10 dB = SNHL) in 15.8% of patients. In their study ITG therapy was administered using a low dose of gentamicin (Approximately 21-24 mg per injection) applied at intervals of a minimum of 27 days.…”

Section: Discussionmentioning

confidence: 93%

Intratympanic Low Dose Gentamicin in Intractable Meniere’s Disease- Chemical Labyrinthectomy Revisited

Choudhary¹,

Basak²,

Ghosh³

et al. 2019

jemds

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 93%

Intratympanic Low Dose Gentamicin in Intractable Meniere’s Disease- Chemical Labyrinthectomy Revisited

Choudhary¹,

Basak²,

Ghosh³

et al. 2019

jemds

View full text Add to dashboard Cite

“…We have tried to match most of the clinical and therapeutic variables but this could not be done for other parameters [2]. Thus, although we did not determine the permeability of the round window to gentamicin, we can consider that this was similar for both groups because the treatment was equally successful.…”

Section: Discussionmentioning

confidence: 99%

“…Between June 1998 and September 2007, 71 MD patients were treated with intratympanic gentamicin [2]. All the patients signed an informed consent that included the requirements established by the International Conference on Harmonization.…”

Section: Patientsmentioning

confidence: 99%

“…The ability of specific aminoglycosides, such as gentamicin, to selectively damage the sensory hair cells of the vestibular system is used as a chemical labyrinthectomy. This approach allows reducing sensitivity of the vestibular system [2]. However, it is difficult to achieve vestibular ablation without causing some damage to hearing.…”

Section: Introductionmentioning

confidence: 99%

“…Clinical variables in Ménière's disease (MD) patients with or without hearing loss after gentamicin therapy[2] One of the patients got cophosis after the treatment NHL non-hearing loss, HL hearing loss, P Probability, NS non significant, M males, F Females, R right, L left, PreT pre-treatment, PostT posttreatment, MTT medium tone threshold, dB decibels, Y yes,…”

mentioning

confidence: 99%

See 2 more Smart Citations

Mitochondrial ribosome and Ménière’s disease: a pilot study

Pacheu-Grau

Pérez-Delgado

Gómez-Díaz

et al. 2012

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Ménière's disease patients experience vestibular disability. When most of medical treatments fail, a chemical labyrinthectomy using aminoglycosides is indicated. However, this process frequently causes hearing damage. Aminoglycosides, interacting with mitochondrial rRNAs, alter mitochondrial protein synthesis and the oxidative phosphorylation system, which provide most of the energy in sensory hair cells. For this reason, we hypothesized that genetic variation in mitochondrial rRNA genes and in two nuclear genes coding for proteins that also modify the susceptibility to aminoglycosides might affect the risk of hearing loss in Ménière's disease patients suffering chemical labyrinthectomy. However, there were no differences in mitochondrial rRNA, TFB1M or MRPS12 genetic variation between those patients that experienced or did not experience hearing loss. This is only a pilot study and larger studies are required to use this therapeutic approach in a rational way and decrease the risk of hearing damage.

show abstract

Chemical labyrinthectomy for the worse ear of adult Nigerians with bilateral Meniere’s disease: preliminary report of treatment outcomes

Olusesi

Hassan

Oyeyipo

et al. 2014

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

The objective of this study was to assess the effectiveness of variable titration, low-dose intratympanic gentamycin (ITG) into the worse affected ear of patients with bilateral Meniere's disease (MD). It is a prospective analytic case series conducted in a tertiary care referral hospital in a developing economy and a tertiary care otologic private ENT clinic. Patients with MD who failed or are intolerant to medical treatment were recruited based on the criteria of definite MD and bilateral ear involvement. 0.75 cc of low-dose (40 mg/ml) buffered gentamycin was injected into the worse affected ear and patients followed up every 2 months, and the regime repeated only if subjective vertigo persists. The patient's age, sex, duration of MD symptom, ear first affected, ear selected for ITG, pure tone threshold at each visit, duration of caloric response (in seconds) for the injected ear, status of tinnitus in both ipsilateral (injected) and contralateral ears, total number of injections before last follow-up, and time since last follow-up are entered into the study protocol and analyzed. Nine patients with a mean age of 45 years and mean duration of symptoms of 59 months were treated. The mean total number of injections was 2.8 with a mean follow-up period of 34 months. Three cases showed drop in pure tone average threshold (2.5-7.5 dB) while an increase in threshold was noted in six cases (2.5-5 dB). All cases demonstrated decrease in duration of response to iced water caloric stimulation in ipsilateral ear, and 4/9 of contralateral ear. The variable titration method using low-dose intratympanic gentamycin directed at worse ear of adult Nigerians with bilateral Meniere's disease appears to be highly effective. More studies are needed.

show abstract

Intratympanic gentamicin in Ménière's disease: our experience

Abstract: This intratympanic gentamicin injection protocol enabled effective vertigo control in most patients, and represents a good alternative to more aggressive techniques for the treatment of Ménière's disease which does not respond to medical treatment.

Cited by 11 publications

References 24 publications

Intratympanic Low Dose Gentamicin in Intractable Meniere’s Disease- Chemical Labyrinthectomy Revisited

Intratympanic Low Dose Gentamicin in Intractable Meniere’s Disease- Chemical Labyrinthectomy Revisited

Mitochondrial ribosome and Ménière’s disease: a pilot study

Chemical labyrinthectomy for the worse ear of adult Nigerians with bilateral Meniere’s disease: preliminary report of treatment outcomes

Contact Info

Product

Resources

About